THERE IS AN INTERESTING NEW DEVELOPMENT associated with the regulation of laboratory developed tests (LDTs) by the Food and Drug Administration (FDA). In recent days, a House committee published draft legislation that directs the FDA to suspend its implementation of the LDT rule. As part of an appropriations bill, the House Appropriations Committee issued a […]
Language in Draft House Bill Directs FDA to Suspend LDT Rule
It is a sign that some members in Congress recognize how FDA’s actions to regulate LDTs can disrupt care
- By Robert Michel
- > From the Volume XXXI, No. 10 - July 22, 2024 Issue
